1. Home
  2. TALO vs HRMY Comparison

TALO vs HRMY Comparison

Compare TALO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

N/A

Current Price

$15.01

Market Cap

2.7B

Sector

Energy

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$32.74

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TALO
HRMY
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.2B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
TALO
HRMY
Price
$15.01
$32.74
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$21.33
★ $48.08
AVG Volume (30 Days)
★ 2.7M
1.0M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.97
EPS
N/A
★ 2.63
Revenue
★ $1,780,070,000.00
$868,453,000.00
Revenue This Year
$31.44
$18.31
Revenue Next Year
$1.94
$14.97
P/E Ratio
★ N/A
$12.53
Revenue Growth
N/A
★ 21.51
52 Week Low
$10.33
$25.90
52 Week High
$18.76
$43.49

Technical Indicators

Market Signals
Indicator
TALO
HRMY
Relative Strength Index (RSI) 37.97 32.34
Support Level $13.96 $32.53
Resistance Level $15.96 $34.16
Average True Range (ATR) 0.74 1.44
MACD -0.07 -0.06
Stochastic Oscillator 32.80 4.78

Price Performance

Historical Comparison
TALO
HRMY

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: